Investor Relations
OSR Health, an Open and Socially Responsible Healthcare Group
Investor Relations
OSR Health, an Open and Socially Responsible Healthcare Group
OSR Health, Inc. (NASDAQ: OSRH) is a healthcare-focused holding company committed to building long-term shareholder value through strategic investment in immuno-oncology, regenerative biologics, and medical device technologies.
Latest Research
https://emerginggrowth.com/profile/osrh/
March 26, 2026: 2nd Materially Positive Event in Recent Months - We remain bullish with a Buy-Emerging rating and a $10.00 price target.
December 4, 2025: New Licensing Deal is a BIG Deal - We remain bullish with a Buy-Emerging rating and a $10.00 price target (on watch for potential upgrade). December 4, 2025.
October 20, 2025: Future Focus - Initiate coverage with a Buy-Emerging rating with a $10.00 price target. October 20, 2025.
Latest News
OSR Health, Inc. (NASDAQ: OSRH) is a healthcare-focused holding company committed to building long-term shareholder value through strategic investment in immuno-oncology, regenerative biologics, and medical device technologies.
Latest Research
https://emerginggrowth.com/profile/osrh/
July 2, 2026: Planning to Reward Long-Term Shareholders - We are bullish with a Buy-Emerging rating and $10.00 target.
May 5, 2026: Specialty-Financed Licensing Deal Delivers Strong De-Risking - We are bullish with a Buy-Emerging rating and $10.00 target.
March 26, 2026: 2nd Materially Positive Event in Recent Months - We remain bullish with a Buy-Emerging rating and a $10.00 price target.
December 4, 2025: New Licensing Deal is a BIG Deal - We remain bullish with a Buy-Emerging rating and a $10.00 price target (on watch for potential upgrade).
October 20, 2025: Future Focus - Initiate coverage with a Buy-Emerging rating with a $10.00 price target. October 20, 2025.
Latest News
 | OSR Health, Inc.ใใReg No. 589-86-01485 Email: ir@osr-health.com
Copyright © OSR Health, Inc. All Rights Reserved. |    |
Frequently Asked Questions
All shareholders who own OSR Health common stock as of the applicable Record Date are eligible to apply for the Shareholder Loyalty CVR Program. Shareholders must complete the required enrollment process and satisfy the applicable program requirements before Contingent Value Rights (CVRs) are issued.
Enrollment is completed by submitting the appropriate application form. U.S. shareholders will need to hold their shares through Direct Registration (DRS) with the Company's transfer agent before enrolling. Non-U.S. shareholders enroll through a separate application process. Full instructions and forms are available on this page.
The Shareholder Loyalty CVR Program is designed to reward long-term ownership. If you sell, transfer, or otherwise dispose of the shares associated with your CVRs before the applicable milestone is achieved, those CVRs will generally terminate and will no longer be eligible to receive additional shares.
Extra shares recieved by reaching are milestones are free to be sold and don't affect future milestone rewards associated with the CVRs from the original shares held on record date.
Once your enrollment has been approved, no further action is generally required. Simply continue to hold your enrolled shares and remain eligible under the terms of the program. If applicable share price milestones are achieved during the program period, eligible U.S. shareholders will receive the corresponding share distributions in accordance with the program terms. Non U.S. shareholders will have to provide a broker attestation on each measurement date to confirm their original shares position.
*The Shareholder Loyalty Program is still subject to receipt of a legal opinion confirming the applicable securities law requirements have been complied with. The program remains subject to change and has not been finalized.
OSR Health, Inc.ใใReg No. 589-86-01485
Email: ir@osr-health.com
US: 10900 NE 4th Street, 2300 Bellevue, WA 98004
KR: B-dong, 3F, 37-36 Hoedong-gil, Paju-si, Gyeonggi-do
CH: Technologiepark Basel, Hochbergerstrasse 60c
Copyright © OSR Health, Inc. All Rights Reserved.
Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months
BELLEVUE, WA /ย ACCESS Newswireย / August 3, 2026 /ย OSR Health, Inc. (NASDAQ:OSRH) today announced that its subsidiary Vaximm AG has completed the analysis of results from two clinical studies evaluating VXM01, an oral DNA vaccine targeting the vascular endothelial growth factor receptor 2 (VEGFR-2), in patients with recurrent glioblastoma.
Prof. Wolfgang Wick, M.D., Chairman of the Neurology Clinic of Heidelberg University and the principal investigator of these trials, commented that "these results are indeed encouraging with regard to moving this concept further in the clinic".
The Company intends to submit these findings to a peer-reviewed scientific journal and is expected to announce further top-line results soon, including the direction of future clinical development of VXM01 and its platform.
Expected Highlights
While the full results will be presented as soon as the publication process allows, the manuscript is expected to include:
VXM01, both as monotherapy and in combination therapy proved to be safe and well tolerated, with no dose-limiting toxicities or high-grade treatment-related adverse event observed. These findings support the excellent safety profile seen in prior studies in subjects with pancreatic adenocarcinoma
Successful activation of patients' immune system against the target
Indication of dose-dependent immunological activity
Supporting biomarker findings consistent with the proposed mechanism of action.
"We are excited by the encouraging results of these glioblastoma studies, adding to our prior evaluations in pancreatic cancer. The data from both trials give further credibility to VXM01, as well as to the oral DNA vaccine platform itself, as an approach to active immunization against a chosen target. We look forward to sharing the full dataset with the scientific community as we continue advancing VXM01 as a unique approach for the treatment of multiple cancer indications." said Dr. Andreas Niethammer, CEO of Vaximm AG.
About VXM01
VXM01 is an oral DNA vaccine designed to elicit a T cell based immune response against the VEGFR-2, a protein involved in tumor angiogenesis and immune suppression within the tumor microenvironment. VXM01 has been evaluated in clinical studies in advanced pancreatic cancer and, more recently, in recurrent glioblastoma, alone and in combination with checkpoint inhibition.
About OSR Health
OSR Health, Inc. (NASDAQ:OSRH) is a global healthcare holding company dedicated to advancing biomedical innovations in health and wellness. Through its subsidiaries, OSR Health engages in immuno-oncology, regenerative biologics, and medical device technologies to improve health outcomes worldwide. Learn more atย www.osr-health.com
Investor Contact
OSR Health, Inc.
Investor Relations
ir@osr-health.com
Forward-Looking Statements
This press release contains forward-looking statements, including statements regarding the timing and content of anticipated preprint and peer-reviewed publications, the significance of preliminary clinical and biomarker findings, and the Company's development plans for VXM01. These statements are based on current expectations and are subject to risks and uncertainties, including that: preliminary findings from small, open-label, uncontrolled early-phase studies may not be replicated in larger or controlled trials;ย publication timing may be delayed or altered through the peer-review or preprint submission process; and the Company's characterization of the platform's cross-indication potential may not be confirmed by future data or by data from other industry participants. The Company undertakes no obligation to update these statements except as required by law.
SOURCE: OSR Health, Inc.
Solutions
Public Relations Products
Investor Relations Products
All Access
Pricing
Professional Services
Blogs
Resources
FAQs
About Us
Our Brands
Contact Us
ยฉ2025 ACCESS Newswire Inc. All rights reserved.ย Terms of Serviceย |ย Privacy Policy